Aura Biosciences, Inc.
Boston, Massachusetts, United States · Biotechnology, Health Care, Therapeutics
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and co
Key facts
- Headquarters
- Boston, Massachusetts, United States
- Employees
- 110
- Industries
- Biotechnology, Health Care, Therapeutics
- Status
- Public (AURA)
- Website
- aurabiosciences.com
- Company page
Recent activity at Aura Biosciences, Inc.
- : SEC 8-K (5.02):
- : SEC 8-K (5.02):
- : SEC 8-K (8.01): On May 11, 2026, the Company updated its corporate presentation for stakeholders including investors and analysts. This presentation details the Company's ongoing and future research and development efforts, including the timelines and expectations surrounding clinical trials for their drug candidates. Important forward-looking statements address potential market impacts and the Company's strategy to meet unmet medical needs in ocular and urologic oncology. The filing includes cautionary notes regarding the inherent uncertainties of these projections, which are submitted as Exhibit 99.2 under Section 18 of the Exchange Act.
- : SEC 8-K (1.01): On May 4, 2026, Aura Biosciences, Inc. entered into an underwriting agreement with Leerink Partners LLC, TD Securities (USA) LLC, and Evercore Group L.L.C. for a public offering of 39,591,000 shares of common stock at $6.00 per share, along with 3,800,000 pre-funded warrants priced at $5.99999. The offering closed on May 5, 2026, with the Underwriters exercising their option to purchase an additional 6,508,650 shares on the same day. The Company raised approximately $280.8 million, which will be used to advance its clinical programs, particularly for early choroidal melanoma, and for general corporate purposes. This agreement marks a significant capital raise for the Company's operations and future development plans.
- : Aura Biosciences Appoints Natalie Holles as Chief Executive Officer
- : SEC 8-K (1.01):
- : SEC 8-K (5.02): On April 30, 2026, Aura Biosciences, Inc. appointed Natalie Holles as Chief Executive Officer and President, succeeding Dr. Elisabet de los Pinos, who will depart from her roles effective the same day. The appointment follows the Board's decision on April 29, 2026, highlighting Ms. Holles' extensive background in the biotech sector, having previously held leadership roles at various notable organizations including Third Harmonic Bio, Inc. and Audentes Therapeutics, Inc. This leadership change is significant for the company as it aims to leverage Ms. Holles' experience in rare diseases to advance its strategic goals. The transition aligns with the company's vision towards enhancing its market position while fostering growth and innovation in its operational framework.
- : SEC 8-K (1.01): On May 4, 2026, Aura Biosciences, Inc. entered into an Underwriting Agreement with Leerink Partners LLC, TD Securities (USA) LLC, and Evercore Group L.L.C., which entails a public offering of 39,591,000 shares of the company's common stock and pre-funded warrants to purchase an additional 3,800,000 shares. The shares were priced at $6.00 each, indicating a significant capital raise effort for the company. This agreement forms a crucial part of Aura Biosciences' strategy to enhance its financial resources and invest in growth initiatives. The transaction is expected to impact the company's market position positively as it expands its capital base.
- : Aura Biosciences Secures $237.55 Million in Public Offering
- : SEC 8-K (8.01): On March 30, 2026, the Company updated its corporate presentation for use in investor meetings. This presentation outlines the Company’s research and development programs, including preclinical studies and clinical trials. It also discusses the potential impact of the Company's product candidates on patient quality of life and market opportunities. The filing includes cautionary statements regarding forward-looking statements and the associated risks involved in the Company's business activities. The strategic implications include the company's plans for commercializing its products and expected financial performance into 2027.
Aura Biosciences, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| May 2026 | Post-IPO Equity | $237.6M |
| Apr 2021 | Venture | $80.5M |
| Jul 2020 | Venture | $10.0M |
| Apr 2019 | Venture | $20.0M |
| Dec 2018 | Venture | $42.3M |
Leadership
- George Ph.D., Director
- Christian Schetter, Director
- Joel Ph.D., Director
- Raj Ph.D., Director
- Casper Breum, Director
- Art Pappas, Director
- Elisabet Ph.D., Executive Officer, Director
- Giovanni Ph.D., Director
- Giovanni Ph.D., Director
- Art Pappas, Director
- Casper Breum, Director
- Raj Ph.D., Director
Verified email and direct lines for Aura Biosciences, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Aura Biosciences, Inc. files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Nov 2026.
Aura Biosciences, Inc. in the news
- Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma - Yahoo Finance (Jun 01, 2026)
- Aura Biosciences to Participate in Upcoming Investor Conference - The Manila Times (Sep 03, 2026)
- Aura Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance (Aug 11, 2026)
- Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion - Yahoo Finance (May 04, 2026)
- Aura Biosciences (Nasdaq:AURA) - Stock Analysis - Simply Wall Street (Oct 28, 2021)
- Aura Biosciences to Participate in Upcoming Investor Conferences - GlobeNewswire (Feb 25, 2026)
- Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights - Yahoo Finance (May 11, 2026)
- Multiple Clinical Complete Responses Demonstrated Following - GlobeNewswire (Oct 17, 2024)
Companies similar to Aura Biosciences, Inc.
- Neurogene · Biotechnology, Health Care, Therapeutics
- 89bio · Biotechnology, Health Care, Therapeutics
- Seres Therapeutics · Biotechnology, Health Care, Therapeutics
- Abeona Therapeutics · Biotechnology, Health Care, Therapeutics
- Verastem Oncology · Biotechnology, Health Care, Therapeutics
About Aura Biosciences, Inc.: questions and answers
What does Aura Biosciences, Inc. do?
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and co
Where is Aura Biosciences, Inc. headquartered?
Aura Biosciences, Inc. is headquartered in Boston, Massachusetts, United States.
How many employees does Aura Biosciences, Inc. have?
Aura Biosciences, Inc. has about 110 employees.
Has Aura Biosciences, Inc. raised funding?
Yes. Fundz has recorded 5 funding events for Aura Biosciences, Inc.. The most recent, Post-IPO Equity of $237.6M, was in May 2026.
What is the latest news on Aura Biosciences, Inc.?
On Aug 11, 2026, SEC 8-K (5.02):
Is Aura Biosciences, Inc. a public company?
Yes. Aura Biosciences, Inc. is publicly traded under the ticker AURA.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy